The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study

Hepatology

Volumn 67, Issue 6, 2018, Pages 2244-2253

  Li, Darrick K ^a   Ren, Yanjie ^b   Fierer, Daniel S ^c   Rutledge, Stephanie ^a   Shaikh, Obaid S ^b   Lo Re, Vincent ^d   Simon, Tracey ^a   Abou Samra, Abdul Badi ^e,f,g   Chung, Raymond T ^a   Butt, Adeel A ^b,e,f,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPATITIS C ANTIBODY; INTERFERON; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALCOHOL ABUSE; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BODY MASS; CANCER INCIDENCE; CLINICAL OUTCOME; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SEROLOGY; SMOKING; SURVIVAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; CHEMICALLY INDUCED; CHRONIC HEPATITIS C; COMPARATIVE STUDY; COMPLICATION; LIVER TUMOR; TIME FACTOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS;

EID: 85047854051     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29707     Document Type: Article

References (28)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
2. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-2882.
3. Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158(5 Pt 1):329-337.
5. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-156.e2.
6. Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol 2014;14:137.
7. Harris RJ, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol 2014;61:530-537.
8. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-726.
9. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-733.
10. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-858.
11. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65:859-860.
12. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-912.
13. ANRS Collaborative Study Group on Hepatocellular Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-740.
14. Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, Anastassopoulos G, et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology 2016;64(S1):10A.
15. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int 2016;36:1275-1283.
16. Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology 2015;62:365-374.
17. Butt AA, Ren Y, Marks K, Shaikh OS, Sherman KE; ERCHIVES study. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther 2017;45:150-159.
18. Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, et al. Liver Fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015;175:178.
19. Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 2016;64:47-57.
20. Omino R, Mittal S, Kramer JR, Chayanupatkul M, Richardson P, Kanwal F. The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Dig Dis Sci 2017;62:1180-1185.
21. Alberti A, Colombo M, Craxì A, Rizzetto M. The dilemma for patients with chronic hepatitis C: treat now or warehouse? Dig Liver Dis 2014;46:27-29.
22. Suda KJ, Halbur DJ, Hunkler RJ, Matusiak LM, Schumock GT. Spending on Hepatitis C Antivirals in the United States, 2009-2015. Pharmacotherapy 2017;37:65-70.
23. Tambourine BM, Sadeghi A, Yang J, Stockl KM, Lew HC, Solow BK, et al. Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population. Am Heal Drug Benefits 2016;9:74-82.
24. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36.
25. Berenguer J, Zamora FX, Aldamiz-Echevarria T, Von Wichmann MA, Crespo M, Lopez-Aldeguer J, et al. Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus. Clin Infect Dis 2015;60:950-958.
26. Klevens RM, Canary L, Huang X, Denniston MM, Yeo AE, Pesano RL, et al. The Burden of Hepatitis C Infection–Related Liver Fibrosis in the United States. Clin Infect Dis 2016;63:1049-1055.
27. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol 2016;65:862-864.
28. Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 2017;37:1122-1127.